Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1997-09-12
2000-05-02
Burn, Brian M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
562621, 562623, A01N 3728
Patent
active
060573694
ABSTRACT:
This invention is directed to compounds of formula I: ##STR1## wherein the variables are as described herein. Compounds within the scope of the present invention possess useful properties, more particularly pharmaceutical properties. They are especially useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. Compounds within the scope of the present invention may also inhibit an MMP, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting MMPs, such disease states involve tissue breakdown and those associated with a physiologically detrimental excess of TNF. The present invention is therefore also directed to the pharmaceutical use of the compounds, pharmaceutical compositions containing the compounds, intermediates leading thereto and methods for the preparation of the compounds and their intermediates.
REFERENCES:
patent: 5240958 (1993-08-01), Campion et al.
patent: 5525629 (1996-06-01), Crimmin et al.
patent: 5691382 (1997-11-01), Crimmin et al.
patent: 5696082 (1997-12-01), Crimmin et al.
Decicco et al., Amide Surrogates of Matrix Metalloproteinase Inhibitors: Urea and Sulfonamide Mimics, Bioorganic & Med.Chem.Letters, vol. 17, No. 18, pp. 2331-2336, 1997.
Potapov et al., Acylation of hydroxylamine by 2-methyl-3-phenylpropanoic acid, Vestn. Mosk. Univ., Ser. 2: Khim. 1983, 24(4), 391-3 (Russ.) (Abstract).
Derwent Patent Preview, WO9839316-A1, Barta et al. Sep. 11, 1998.
Derwent Patent Preview, WO9834915-A1, Robinson, Aug. 13, 1998.
Derwent Patent Preview, WO9839315-A1, Becker et al. Sep. 11, 1998.
Derwent Patent Preview, WO9839313-A1, Getman et al., Sep. 11, 1998.
Derwent Patent Preview, WO98329326-A1, Freskos et al., Sep. 11, 1998.
Derwent Patent Preview, WO9838163-A1, Venkatesan et al., Sep. 3, 1998.
Derwent Patent Preview, WO9837877-A1, Venkatesan et al., Sep. 3, 1998.
Burns Christopher J.
Condon Steven M.
Djuric Stevan W.
Groneberg Robert D.
McGeehan Gerald M.
Burn Brian M.
Davis Brian J.
Parker III Raymond S.
Rhone-Poulenc Rorer Pharmaceuticals Inc.
LandOfFree
Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) h does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) h, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) h will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1594394